User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Share Name Share Symbol Market Type Share ISIN Share Description
Cvs Group Plc LSE:CVSG London Ordinary Share GB00B2863827 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  20.00 0.87% 2,320.00 2,310.00 2,315.00 2,345.00 2,270.00 2,345.00 321,905 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 427.8 9.9 8.1 286.4 1,641

Cvs Share Discussion Threads

Showing 601 to 623 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
Berenberg Buy UP FROM 1,200.00 TO 1,400.00 Reiterates
RNS Number : 2678C CVS Group plc 07 February 2020 7 February 2020 CVS Group plc ("CVS" or the "Company" and, together with its subsidiaries, the "Group") Trading Update CVS, one of the UK's leading providers of integrated veterinary services, provides the following update on headline trading in respect of the financial half year ended 31 December 2019 ("H1 2020"). The Company will announce its interim results, for the six months ended 31 December 2019, on 27 March 2020. Overview The Board is pleased to announce that the improved trading performance delivered in the second half of the financial year to 30 June 2019, and the encouraging start to the new financial year, as announced at the time of our Annual General Meeting on 28 November 2019, has continued for the remainder of the half year to 31 December 2019. H1 2020 Performance In H1 2020, the Group's total sales increased by 15.0% and like-for-like sales(1) ("LFL") increased by 8.4%, in each case compared to the financial half year ended 31 December 2018 (H1 2019). Within the Group's core Practice division, total sales increased by 13.7% and Practices LFL(2) sales increased by 7.4%, in each case compared to H1 2019. Gross margins(3) for the Group in H1 2020 were 76.0% compared to 76.2% in H1 2019. This slight reduction primarily results from strong sales growth for Animed Direct, our online dispensary, for which margins are lower and which accounted for 6.3% of Group sales in H1 2020 (H1 2019: 5.3%). Practice division gross margins improved to 78.3% in H1 2020 from 77.8% in H1 2019. Within the Practice division, the growth in total and LFL sales and the improvement in gross margin largely reflect the continuing focus on high quality clinical work, including increased volume and value of referrals within the Group, and the benefit of modest price increases previously described in our November 2019 update. Employment costs for the Group in H1 2020 were 51.0% of total sales, compared to 51.6% in H1 2019. This reduction stems from a continued focus on the retention of clinical staff and the Group is pleased to announce that its veterinary surgeon vacancy rate averaged 7.8% in H1 2020 (H1 2019: 8.7%). As a result of the above, CVS expects to report H1 2020 Adjusted EBITDA(4) that is materially above that delivered in H1 2019. This is in line with management expectations and is attributed to the better performance in H1 2020 as well as the weaker comparative in H1 2019. Outlook As previously stated, the comparatives become more challenging in the second half of the current financial year, given the improved performance seen in H2 2019. The continuing positive trends in key performance indicators provide further assurance that the Group is trading in line with management's expectations for the full year.
Giulia Bottaro 08:04 Fri 07 Feb 2020 viewCVS Group CVS Group on the mend as vet shortage eases The vet group has recovered since last year's profit warning due to a shortage of vets CVS Group - CVS Group continues to improve trading CVS Group PLC (LON:CVSG) has bounced back from a profit warning a year ago sparked by a shortage of vets, which pushed up staffing costs. The AIM-listed pet care firm expects underlying earnings (EBITDA) this year to be “materially ahead” of the previous year helped by easier comparatives. In the six months to 31 December, like-for-like sales rose 8% while total sales were up 15% over the half-year. Gross margins dipped by 0.2% to 76% due to higher revenue from the low-margin online dispensary segment though employment costs as a percentage of sales eased slightly to 51%. Net debt narrowed 5% to £97mln. Add related topics to MyProactive
I believe the thesis. Although I don't see this as completely bulletproof, I like the steps management have taken. Long-term looks fine, near term depends. Brexit didn't help, but if homebuilders are on their way up I don't see why vet services shouldn't participate in the market as well.
lovely looking chart but I must check fundamentals to see if it appears to be overbought ! anyone any thought on that please ?
CVS Group PLC CVSG Peel Hunt Buy 1,150.00 - Reiterates
A big reason why Innes sold one third of his shares would be taxation. As an employee of CVS his shares are treated as a business for CGT and taxed at 10% on gains. After he has left CVS in the next few weeks he would be taxed like everyone else at 40%.
magnum opus
11/21/2019 Ex-dividend day for final dividend 11/29/2019 Annual General Meeting
If there's an issue why doesn't he sell all of his shares? It's hard to tell, maybe he was able to tax off-set this year or he had reason for other commitments. Plus what's his history? Has he always sold suspiciously ahead of negative releases? Don't get distracted from the market positioning and business model. That said, it's had a very good run recently but I don't see major drama.
The chickens came home to roost! See my earlier comments on questionable share dealing and top executive sackings! Once again he snaffles share option sell downs and further millions two weeks ago on way out the door!
Wonder why Inness left so quickly??
CVS Group PLC CVSG Peel Hunt Buy 1,050.00 - Reiterates
NOVEMBER 21/2019 Ex-dividend day for final dividend
Business Summary CVS Group plc is a holding company. The principal activities of the Company are to operate animal veterinary practices, veterinary diagnostic businesses, pet crematoria and an online pharmacy and retail business. Its segments are Veterinary Practice, Laboratories, Pet Crematoria and Animed Direct. The Veterinary Practice segment offers treatment for companion animals, equine and farm animals. The Laboratories segment provides diagnostic services to its veterinary practices and third-parties. Its laboratories provide Biochemistry, hematology, histology, serology and advanced allergy testing. The Pet Crematoria segment offers pet cremation services to its veterinary practices, third-party practices and directly to pet owners. The Animed Direct segment sells prescription and non-prescription drugs, pet food and other animal related products through its Website. It operates approximately 360 veterinary practices, four diagnostic laboratories, seven pet crematoria and an online dispensary. Number of employees : 6 150 people. Https://
cheers joseki
You have mistaken CVS the US pharma chain with the CVSG pet business. florenceorbis 5 Sep '19 - 08:27 - 564 of 569 0 1 0 WASHINGTON -- A federal judge on Wednesday approved a Justice Department settlement that allowed CVS Health Corp.'s nearly $70 billion acquisition of health insurer Aetna Inc.
A decent quarter, execution just needs to stay real and simple. Especially this environment. The market will punish mistakes and bad news.
Peel Hunt Buy down from 1,050.00 to 950.00 Reiterates
adrian j boris
Dividends It is proposed to pay a dividend of 5.5p per share in December 2019, a 10.0% increase on the 5.0p per share paid in 2018. The financial performance of the business and its strong cash generation support an increase in dividends whilst enabling the Group to retain sufficient funds for further investment in the business. Outlook CVS operates in a sector with favourable market and consumer trends, with pet owners increasingly willing to spend money on their pets and medical enhancements increasing the range of services we can offer. Despite continued uncertainty over Brexit with the potential for a "hard" Brexit increasingly likely, the Board is confident that CVS is well positioned to avoid significant adverse impacts from the UK's decision to exit the EU. Pharmaceutical manufacturers and wholesalers are increasing their stock levels in order to reduce the risk of supply shortages and following the acquisition of Vet Direct, CVS now controls more of its equipment and consumables supplies. The pace of growth in the UK economy may be impacted by Brexit uncertainty, but the veterinary sector has proven to be resilient in past periods of economic downturn and the Board believes CVS is sufficiently resilient to withstand any potential future downturn. The performance of the business was considerably improved in the second half of the financial year and the Board is confident that the Group is well placed to deliver further enhancement in shareholder value in the forthcoming financial year. I would like to thank all of our colleagues for their contribution to the past financial year. Their professionalism, dedication and commitment to providing the highest levels of clinical care to our customers and their animals forms the heart of our business. I look forward to working with them to continue the successful growth of CVS in the future. Richard Connell Non-Executive Chairman 27 September 2019
-- Revenue up 24.2% to GBP406.5m -- Like-for-like sales growth for the Group of +5.2% (5) -- Healthy Pet Club members up 10.8% to 401,000 -- Adjusted EBITDA up 14.5% to GBP54.5m -- Adjusted earnings per share increased 10.1% to 46.7 pence per share -- Cash generated from operations up 11.6% to GBP52.1m -- Profit before income tax down 17.0% to GBP11.7m due to amortisation costs in relation to acquisitions -- Leverage reduced to 2.08x at 30 June 2019 -- Significant improvement in second half -- Now operate 510 surgeries across the UK, the Netherlands and the Republic of Ireland
CVSG Peel Hunt Buy UPS TARGET FROM 950.00 to 1,050.00 Reiterates
SEPTEMBER/27/2019 FY 2019 Earnings Release
This article is being republished as part of our daily reproduction of articles that also appeared in the U.S. print edition of The Wall Street Journal (September 5, 2019). WASHINGTON -- A federal judge on Wednesday approved a Justice Department settlement that allowed CVS Health Corp.'s nearly $70 billion acquisition of health insurer Aetna Inc., removing a cloud of uncertainty for the merged company. U.S. District Judge Richard Leon had spent months questioning whether the settlement did enough to protect competition and consumers in health-care markets, raising the possibility that he might not approve it. The judge, in a first for a court review of a government merger settlement, convened hearings to consider live witness testimony from the deal's critics who said the Justice Department's deal with the companies was inadequate. Judge Leon on Wednesday said the critics' testimony ultimately was unpersuasive. He said the health-care markets at issue in the case "are not only very competitive today, but are likely to remain so post-merger." The settlement "is well within the reaches of the public interest," the judge concluded. The Justice Department approved the CVS-Aetna deal nearly a year ago, requiring CVS to sell off Aetna's Medicare prescription drug-plan business. CVS completed the acquisition weeks later and has been moving forward with the Aetna business ever since. It sold Aetna's Medicare assets to WellCare Health Plans Inc., as the department required. The merger combined the nation's third-largest health insurer with CVS's sprawling network of pharmacies and its pharmacy-benefit-management business. The companies argued that their combination could lower costs and improve health care for consumers. "CVS Health and Aetna have been one company since November 2018, and today's action by the district court makes that 100 percent clear," a CVS spokesman said. "We remain focused on transforming the consumer health care experience in America." An array of parties, including the American Medical Association and consumer groups, lodged objections to the merger, saying the deal would have anticompetitive effects throughout the health-care supply chain, giving CVS an outsize role. Judge Leon said while the complaints warranted serious consideration, the evidence wasn't sufficient to reject the government's settlement with the companies. He rejected critics' arguments that the merger would harm markets for Medicare prescription drug plans. He also said CVS is unlikely to use its strong market position in the management of pharmacy benefits to disadvantage companies that compete with CVS's newly expanded health-insurance business. The AMA expressed disappointment in the ruling. "Despite an unprecedented review that dragged many details of this merger into the light, today's decision ultimately fails patients, will likely raise prices, lower quality, reduce choice, and stifle innovation," AMA president Patrice A. Harris said. Wednesday's ruling will likely come as a relief to the Justice Department, which has seen repeated difficulties in Judge Leon's courtroom. The judge, while questioning whether the DOJ did enough to address the CVS-Aetna merger, last year rejected the department's bid to block AT&T Inc. from acquiring entertainment company Time Warner. Assistant Attorney General Makan Delrahim, the department's antitrust chief, said the settlement "provides a comprehensive remedy to the harms the Justice Department identified." Approval of the settlement "protects seniors and other vulnerable customers," he said. Write to Brent Kendall at (END) Dow Jones Newswires September 05, 2019 02:47 ET (06:47 GMT)
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210508 23:12:32